en · de · es · fr · pt
glossary-desk.peptides7501.com › Guide › Sr9009 Background And Receptor Mechanism — Research Overview

Sr9009 Background And Receptor Mechanism — Research Overview

By Editorial Desk · published 2026-06-18 · last reviewed 2026-07-27 · Guide

A practical reference on SR9009: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

This page was last updated on 2026-07-27 and is reviewed periodically as new material appears.

SR9009 Background and Receptor Mechanism

Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.

SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.

SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.

Background and Research Status

REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.

Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.

Sr9009 at a glance

PropertyValueNotes
Chemical classSynthetic REV-ERB agonistSmall-molecule nuclear receptor ligand
AppearanceOff-white to pale yellow solidTypical for research-grade powder
Solubility classSoluble in DMSO; low water solubilityCommon stock solutions use organic solvent
Typical stock solventDimethyl sulfoxideUsed for laboratory assays
Common analytical methodHPLC with UV or mass detectionUsed for identity and purity checks

Background and Mechanism

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.

At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.

Related pages on this site

Background and Receptor Pharmacology

Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.

Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.

Supporting material

== Synthesis == PreproGRP begins with signal peptidase cleavage to generate the pro-gastrin-releasing-peptide (proGRP), which is then processed by proteolytic cleavages, to form smaller GRP peptides. These smaller peptides are released by the post-ganglionic fibers of the vagus nerve, which innervate the G cells of the stomach and stimulate them to release gastrin. GRP regulates numerous functions of the gastrointestinal and central nervous systems, including release of gastrointestinal hormones, smooth muscle cell contraction, and epithelial cell proliferation.

=== Preclinical === Acne vaccine – immunostimulant ADA-308 – antiandrogen (androgen receptor antagonist) Research programme: acne vulgaris therapeutics - Attillaps Pharmaceuticals – acetylcholinesterase inhibitors

In more severe cases it is a consequence of dilation of the right ventricle, leading to displacement of the papillary muscles which control the valve's ability to close. Dilation of the right ventricle occurs secondary to ventricular septal defects, right to left shunting of blood, eisenmenger syndrome, hyperthyroidism, and pulmonary stenosis. Tricuspid insufficiency may also be the result of congenital defects of the tricuspid valve, such as Ebstein's anomaly.

Main dishes are usually centred on a sauce or stew of simsim, groundnuts, beans or meat. The starch traditionally comes from posho (maize meal) or matooke (steamed and mashed green banana) in the central or kalo (an ugali dish made from millet) in the north, east and west. Posho or millet is cooked as a porridge for breakfast. For main meals, white maize flour is added to the saucepan and stirred into the posho until the consistency is firm. It is then turned out onto a serving plate and cut into individual slices (or served onto individual plates in the kitchen). Cassava, yam, and African sweet potato are also eaten; the more affluent include white (often called "Irish" or "Western"/mazungu) potato and rice in their diets. Soybeans were promoted as a healthy food staple in the 1970s and this is also occasionally eaten for breakfast, although mostly used as feed for animals. Chapati, similar to Asian flatbreads, are also part of Ugandan cuisine.

Sources: en.wikipedia.org

Supporting material

He strengthened the squad by signing Alexis Sánchez from Barcelona in July 2014, who started in the 2014 FA Community Shield that Arsenal won by beating Manchester City 3–0, and during the course of 2014–15, Wenger promoted Francis Coquelin and Héctor Bellerín into the first team. Wenger won his sixth FA Cup in May 2015, which placed him alongside George Ramsay as the most successful manager in the competition's history. Wenger guided the club to an improved third place in the league that season, and the club saw further improvement in the 2015–16 season as they finished as league runners-up, while retaining the FA Community Shield by defeating Chelsea 1–0.

Taliban officials had not commented on the reports of airstrikes on military sites in Kandahar province. Pakistani troops attacked and destroyed Taliban border checkpoints in Zabul Province inflicting losses. Taliban authorities claimed that Pakistani conducted mortar strikes into Samkani district in Paktia province and artillery into Kunar with 82 shells hitting Sarkano District, 15 striking Dangam District and four in Shultan District. The Taliban claimed that one child was wounded and several residential properties were damaged, elsewhere, skirmishes in Kamdesh district of Nuristan killed two civilians, a mortar strike in Khost wounded a child and a civilian was killed and another wounded in skirmishes in Shkin District of Paktika Province. A policeman was killed in a militant sniper attack in Bajaur. A cylinder bomb attack on Miranshah camp killed two government officials. The Norwegian Refugee Council reported that a Pakistani artillery attack on an earthquake-affected refugee camp in Khas Kunar District, Kunar province, resulted in three people being killed and seven others being injured, while forcing 650 families from the camp to flee to safety. An Afghan media outlet reported that the Taliban were forcibly recruiting and deploying fighters, including civilians, from northern and northeastern Afghanistan to front lines along the Pakistan border, sometimes using financial incentives. It said that many were sent without their families' consent, causing concern among residents.

===== Uruguay ===== In December 2024, Lula visited Uruguay to attend a Mercosur summit that culminated in the signing of the EU–Mercosur Association Agreement. He also met with former Uruguayan former president José Mujica, whom he decorated with the Order of the Southern Cross, Brazil's highest award, and president-elect Yamandú Orsi.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.

How does SR9009 work?

It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.

Is SR9009 a proven performance enhancer?

No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.

What is SR9009?

It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.

Network